title: Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes.
abstract: To explore further topical antiviral therapy for recurrent genital herpes, 188 culture-proven patients were randomized to receive treatment with topical interferon-alpha in high-dose (10(6) IU/g with 1% nonoxynol-9 in 3.5% methylcellulose) or low-dose (10(3) IU/g with 0.1% nonoxynol-9 in 3.5% methylcellulose) treatments or placebo (3.5% methylcellulose, alone), applied three times daily for 5 days. Of these, 105 experienced prodromal symptoms within the study period and applied the medication, of whom 99 could be evaluated for efficacy. Patients were followed with daily clinical assessments and cultures until reepithelialization. The median time to negative virus culture in high-dose recipients was 2.5 days compared with 3.9 days for placebo recipients (P = .023), and a significant dose response was observed (P = .016). Antiviral effects were more prominent in men than women. High-dose recipients also had reduced median duration of symptoms to 2.7 days from 3.7 days for placebo recipients (P = .03), with a significant dose-response relationship (P = .047). Effects on duration of symptoms were more prominent in women. Times to complete reepithelialization in those who applied the drug during the prodromal phase were 5.8 days for high-dose recipients compared with 6.5 days for placebo recipients (P = .053). A multivariate ranked linear model analysis of four efficacy variables (crusting, healing, virus shedding, symptom duration) also favored the high-dose gel (P = .015). High-dose topical interferon-alpha preparation is effective for patients with recurrent genital herpes. Applied early in the course of a recurrent episode, this treatment is safe and may provide a topical alternative to other types of therapy in the future.
authors.affiliation: Department of Medicine, University of British Columbia Herpes Clinic, University Hospital-UBC Site, British Columbia Centre for Disease Control, Vancouver.
authors.forename: S L
authors.initials: SL
authors.lastname: Sacks
authors.forename: T L
authors.initials: TL
authors.lastname: Varner
authors.forename: K S
authors.initials: KS
authors.lastname: Davies
authors.forename: M L
authors.initials: ML
authors.lastname: Rekart
authors.forename: H G
authors.initials: HG
authors.lastname: Stiver
authors.forename: E R
authors.initials: ER
authors.lastname: DeLong
authors.forename: P W
authors.initials: PW
authors.lastname: Sellers
mesh_terms: D000287:Administration, Topical; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006558:Herpes Genitalis / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017137:Nonoxynol; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012737:Sex Factors
chemical_list: D007370:Interferon Type I; D017137:Nonoxynol; D011092:Polyethylene Glycols